首页 News 正文

The second Alzheimer's disease drug approved by the United States: Eli Lilly R&D, with an annual treatment cost of $32000

因醉鞭名马幌
232 0 0

After more than half a year of delay from the initial expected approval time, Lilly's Alzheimer's disease treatment drugs have finally been approved in the United States.
On July 2nd local time, Eli Lilly announced that the US Food and Drug Administration (FDA) has approved Kisunla (commonly known as Donanemab) for the treatment of early symptomatic adult Alzheimer's disease (AD) patients, including those with mild cognitive impairment and those in the mild dementia stage of neurodegenerative diseases.
Lilly initially expected Donanemab to be approved by the end of 2023, but the actual approval time has been pushed back and forth. This approval makes Donanemab the second drug in the US market aimed at slowing down the progression of Alzheimer's disease. Lilly stated that this drug is also the first anti amyloid protein drug that can stop treatment after removing amyloid plaques, reducing the number of infusions and lowering treatment costs.
In the global pharmaceutical industry, many pharmaceutical companies are increasing their research and development of Alzheimer's disease drugs, but the results are not ideal. According to data from the American Association for Drug Production and Development, the global cumulative R&D investment in Alzheimer's disease exceeds 600 billion US dollars, with over 300 failed clinical drugs and a failure rate of 99.6%. Therefore, Alzheimer's disease drugs are also known as the "R&D black hole".
With more and more new drugs being approved, the pharmaceutical industry is emerging from the "death valley" of Alzheimer's disease research and development, and competition in the field of Alzheimer's disease is also on the verge of breaking out.
Alzheimer's disease (AD) is known as the "eraser in the brain", and patients' thinking, memory, and independence are impaired, not only affecting their quality of life, but even leading to death. In July 2023, Japanese pharmaceutical company Eisai's lenkanizumab was fully approved in the United States for the treatment of Alzheimer's disease, becoming the first AD drug in 20 years to receive full FDA approval, while Eli Lilly's Kisumla is the second drug in the US market aimed at slowing down the progression of Alzheimer's disease.
Abnormal deposition of beta amyloid protein (A β) is one of the widely recognized mechanisms of Alzheimer's disease in the industry. Lilly's Donanemab and Eisai's lencamab are both anti amyloid beta (A β) drugs.
The approval of Eisai's lencamab is based on phase III data from a large-scale global Clarity AD clinical trial. The main endpoint of this experiment is the Global Cognitive and Functional Scale, also known as CDR-SB. Compared to placebo, lencamab treatment reduced the clinical decrease in CDR-SB by 27% at 18 months.
Lilly's approval this time is based on the results of the TRAILBLAZER-ALZ 2 experiment. According to research data disclosed by Lilly in July 2023, among participants with mild cognitive impairment, donanemab slowed decline by 60% on the iADRS (Alzheimer's Disease Comprehensive Rating Scale) and CDR-SB by 46%.
In addition to different research data, the frequency and price of medication for the two drugs are also different: lencamab needs to be administered every two weeks, and Donanemab needs to be administered every four weeks. The unit price of Eli Lilly's Alzheimer's disease medication is more expensive, reaching $695.65 per bottle, with an annual treatment cost of $32000, while the treatment cost of lencamab in the United States is about $26500. However, Lilly emphasizes that Donanemab can stop treatment after removing amyloid plaques, and the actual total cost of treatment for patients will depend on when they complete the treatment.
In January of this year, lencamab was approved in China. On June 28th, Weicai China announced that the drug has officially been launched in China. According to public information, the drug has not yet been included in medical insurance, and the patient's self funded annual treatment cost is about 180000 yuan. If calculated based on the clinical trial of completing one treatment cycle in 18 months, the total treatment cost for one and a half years is around 270000 to 300000 yuan.
When is Donanemab expected to arrive in China after being approved in the United States? Currently, Lilly China has not disclosed any relevant information. Many domestic pharmaceutical companies are also expanding their research and development of Alzheimer's disease drugs, mostly in the early stages. According to a research report from Galaxy Securities, there are a total of 34 new clinical AD drugs in China, involving listed pharmaceutical companies such as Hengrui Pharmaceutical (600276), Xiansheng Pharmaceutical (2096. HK), and Tonghua Jinma (000766).
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 【科技记者古尔曼:苹果计划于12月第一周发布iOS 18.2系统更新 带来更多人工智能功能】科技记者古尔曼透露,苹果计划于12月第一周发布iOS 18.2系统更新。iOS 18.2将为iPhone 15 Pro机型和所有iPhone 16机型带来更多 ...
    cristianna
    昨天 17:32
    支持
    反对
    回复
    收藏
  •   近日,爱立信中国区总裁方迎在接受《经济参考报》记者采访时表示,5G技术在全球范围内得到了迅速发展,但面临商业潜力未能充分挖掘、网络运营难度较以往更高两大挑战。因此,运营商在继续5G网络部署的同时,应关 ...
    blueskybb
    昨天 15:05
    支持
    反对
    回复
    收藏
  • 【特斯拉首次聘请了一位品牌大使】特斯拉近日公布了首位品牌大使韩国奥运射击选手金艺智,这一举动有些出人意料,毕竟它曾经对广告的态度十分不屑。 ...
    xyyg
    昨天 13:34
    支持
    反对
    回复
    收藏
  •   证券时报网讯,纽约州共同退休基金在第三季度对一些科技巨头的股票进行了调整。该基金是美国第三大公共养老金,管理着2677亿美元的资产。该基金三季度出售了231,600股Palantir 股票,将其持股数量降至110万股。 ...
    LEMONKEITH
    昨天 15:12
    支持
    反对
    回复
    收藏
因醉鞭名马幌 注册会员
  • 粉丝

    0

  • 关注

    0

  • 主题

    43